New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
DESIGN THERAPEUTICS INC
NASDAQ:DSGN (2/11/2025, 3:11:59 PM)
3.79
-0.47 (-11.03%)
DSGN Latest News and Analysis
a day ago - ChartmillMonday's pre-market session: top gainers and losersDiscover the top movers in Monday's pre-market session and stay informed about market dynamics.
